Head & Senior Consultant
Hepato-pancreato-biliary and Transplant Surgery
Head & Senior Consultant
Surgery and Surgical Oncology, SGH & NCCS
Chief of Transplant Services, SGH Campus, SingHealth Duke-NUS Transplant Centre
SingHealth Duke-NUS Transplant Centre
Professor Goh is presently Head of the Department of Hepatopancreatobiliary and Transplant Surgery at Singapore General Hospital and the National Cancer Centre Singapore. He is also the Director of Singhealth Liver Transplant Service, and Surgical Director of the National Liver Transplant Program, Ministry of Health Singapore. He is a highly-experienced and high-volume subspecialty HPB/ transplant surgeon whose clinical practice focuses on the management of complex benign and malignant (cancers) conditions affecting the liver, pancreas, biliary tract and gallbladder.
As of 2025, he has performed well over 2,000 major subspecialty HPB/ transplant surgeries (>1,200 liver, >700 pancreas/ biliary, >500 recipient/ donor transplant surgeries) after completing surgical training and becoming a Singapore board-certified specialist surgeon. He is the only surgeon in Singapore certified by both the American Society of Transplant Surgeons (ASTS) and Ministry of Health in abdominal(liver/kidney/pancreas) transplantation and is the current surgical director of the National Liver Transplant Program, National Organ Transplant Unit, Ministry of Health, Singapore. He had previously worked as a surgical fellow for 2 years at the world-renowned Mayo Clinic Rochester performing numerous complex surgical procedures. He is well-recognized as an international thought leader due to his vast clinical experience and extensive research work in the field. Dr Goh has received several awards and has been an invited member to numerous international expert consensus panels.
Presently, he is one of the most experienced surgeons in Southeast-Asia for minimally-invasive/ laparoscopic HPB surgery. Since returning to Singapore in 2011 (till 2025), he has personally performed over 1,000 laparoscopic and robotic major HPB surgeries (> 630 minimally-invasive liver resections, > 270 minimally-invasive pancreas surgeries, >150 minimally-invasive major biliary procedures) as the lead surgeon and mentored/proctored over a dozen subspecialty regional colleagues in many more such procedures. He is presently widely-recognized as an international expert in minimally-invasive HPB surgery. Regionally, Dr Goh is a pioneer in advanced laparoscopic HPB surgery and is frequently invited to lecture and proctor local/regional surgeons. He pioneered robotic HPB surgery in the region in 2013 and has personally performed over 200 robotic major HPB surgeries as the main console surgeon. He is the only local robotic HPB proctor and has tutored over a dozen subspecialty colleagues in Southeast Asia in numerous robotic HPB procedures. He is also the only local HPB surgeon listed in the Intuitive Surgery (Da Vinci robotic surgery) surgeon locator and remains only one of a handful of high-volume HPB surgeons regionally who routinely performs laparoscopic or robotic surgery for highly complicated procedures such as major and anatomical hepatectomies, adult living donor transplant hepatectomy, pancreatectomies (Whipples procedure/ pancreatoduodenectomy), associated liver partition and portal vein ligation for staged hepatectomy (ALPPS), repair of bile duct injuries, resections for bile duct/ gallbladder cancers, giant liver tumors and repeat resection for recurrent cancers with a high-success rate.
Dr Goh frequently uses transplant oncology techniques to perform complex multi-organ resections with major vascular reconstructions for borderline-resectable cancers which may be considered inoperable by other surgeons. He is also experienced in treating rare conditions such as polycystic liver disease, giant malignant and benign tumors, choledochal cyst, gastrointestinal stromal tumours (GIST), neuroendocrine (carcinoid) tumours and pancreatic cystic tumours such as intraductal papillary mucinous neoplasms (IPMN), frequently using minimally-invasive surgical techniques. He is also the Principal Investigator of the first regional clinical trial on the application of Histotripsy for liver cancers (HALT).